Drug news
BTG licence of rights to Voraxaze for Methotrexate Toxicity
BTG has agreed to licence Ohara Pharmaceutical the rights in Japan to develop and market Voraxaze (glucarpidase) its treatment for Methotrexate Toxicity due to impaired renal function. The drug is filed in the USA and EU and its PDUFA action date is 17 January 2012.